[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642622":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":52,"collaborators":19,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":19,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":19,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":19,"overallStatus":72,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Danatlas Pharmaceuticals Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DAT-2645 tablet","EXPERIMENTAL","Monotherapy under the recommended dose (RDE)",[13],"Drug: DAT-2645 tablet",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Oral administration with 21 days each cycle",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Clinical Operation Director","CONTACT","+86-10-67803200","information@danatlas.com",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Regulatory Affairs Manager","+86-13717825107","Huixian.chen@danatlas.com",[31,44],{"facility":32,"status":19,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":19},"Research site","Guangzhou","Guangdong","510050","China","CN",{"type":39,"coordinates":40},"Point",[41,42],113.25,23.11667,{"lat":42,"lon":41},{"facility":32,"status":19,"city":45,"state":19,"zip":46,"country":36,"countryCode":37,"cosmosGeoPoint":47,"geoPoint":51,"contacts":19},"Beijing","100021",{"type":39,"coordinates":48},[49,50],116.39723,39.9075,{"lat":50,"lon":49},{"type":53,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100642622","phase-2-a-study-of-dat-2645-in-patients-with-brca12-mutations-or-hrd-positive-ovarian-cancer-100642622",false,"NCT07652073","A Study of DAT-2645 in Patients With BRCA1\u002F2 Mutations or HRD-Positive Ovarian Cancer","A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of DAT-2645 in Patients With BRCA1\u002F2 Deleterious Mutations or HRD-Positive Advanced\u002FMetastatic Ovarian Cancer","Inclusion Criteria:\n\n* sign a written informed consent form\n* At least 18 years of age (inclusive)\n* Epithelial ovarian cancer confirmed by histopathology or cytopathology\n* BRCA1\u002F2 mutation or HRD-positive status\n* Patients who have failed standard treatment or are unable to tolerate standard treatment\n* Patients must have received no more than five prior treatment lines\n* At least one measurable lesion\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Bone marrow reserve and organ function must meet the requirements\n* Negative result on a blood pregnancy test for a woman of childbearing age\n\nExclusion Criteria:\n\n* Received small-molecule chemotherapy or targeted therapy within 2 weeks or 5 half-lives prior to the first dose\n* Received treatment with an anticancer biological therapy within 4 weeks prior to the first dose\n* Underwent major surgery within 4 weeks prior to the first dose\n* Has previously received treatment with a PARG inhibitor\n* Inadequate response to previous PARP inhibitor maintenance therapy\n* With central nervous system metastases\n* Patients with clinically significant cardiovascular or cerebrovascular diseases\n* Uncontrolled active infections requiring intravenous antibiotics or hospitalization\n* Adverse reactions from prior anticancer therapy have not yet resolved to a grade ≤1","FEMALE","18 Years",{"count":64,"type":65},30,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645",[71],"Advanced or Metastatic Ovarian Cancer","NOT_YET_RECRUITING","2026-06-21",{"date":75,"type":76},"2026-06-25","ACTUAL",{"date":78,"type":65},"2026-06-15",{"date":80,"type":65},"2028-03-30",{"name":5,"class":6},2]